Combination immune checkpoint inhibitor-induced hypophysitis: A case report

Nathan Hyson  
*Henry Ford Health System*

Allen Wrubel  
*Henry Ford Health System*

Suresh C. Patel  
*Henry Ford Health System*

Ishani Dalal  
*Henry Ford Health System*

John Corrigan  
*Henry Ford Health System*

See next page for additional authors

Follow this and additional works at: [https://scholarlycommons.henryford.com/merf2019caserpt](https://scholarlycommons.henryford.com/merf2019caserpt)

**Recommended Citation**
Hyson, Nathan; Wrubel, Allen; Patel, Suresh C.; Dalal, Ishani; Corrigan, John; Marin, Horia; and Griffith, Brent, "Combination immune checkpoint inhibitor-induced hypophysitis: A case report" (2019). *Case Reports*. 83.  

This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Case Reports by an authorized administrator of Henry Ford Health System Scholarly Commons.
Authors
Nathan Hyson, Allen Wrubel, Suresh C. Patel, Ishani Dalal, John Corrigan, Horia Marin, and Brent Griffith

This poster is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/merf2019caserpt/83
Combination immune checkpoint inhibitor-induced hypophysitis: A case report and review of the clinical and imaging findings

Allen Wrubel MD, Nathan Hyson MD, Suresh Patel MD, Ishani Dalal MD,
John Corrigan MD, Horia Marin MD, Brent Griffith MD
Department of Radiology - Henry Ford Hospital, Detroit, Michigan

Goals and Objectives

1. Describe a case of immune-checkpoint inhibitor-induced hypophysitis in a patient on combination immune checkpoint inhibitor therapy for metastatic melanoma.
2. Discuss the imaging findings of autoimmune hypophysitis associated with immune checkpoint inhibitors.
3. Familiarize the audience with the occurrence of this rare complication of a novel therapy, so that it may be more readily recognized.

Introduction

Immune checkpoint inhibitors have emerged as a promising new class of anti-cancer drugs. Unfortunately, while potentiating the immune system’s response to cancer cells, these drugs also place the patient at risk for the development of immune-related adverse events (irAEs). Most often, the gastrointestinal tract and skin are involved. However, involvement of the endocrine system also occurs. While thyroid dysfunction is the most common endocrinological irAE, hypophysitis is also frequently seen - and is especially associated with ipilimumab (1).

Case Presentation

A 60-year-old male undergoing combination immune checkpoint therapy with nivolumab (an anti-PD-1 antibody) and ipilimumab (an anti-CTLA-4 antibody) for metastatic melanoma developed headaches. An MRI of the brain was obtained and demonstrated new enlargement of the pituitary.

Initial differential considerations included a metastatic lesion to the pituitary stalk, however the patient was also found to be hypothyroid. Further endocrinological evaluation revealed low testosterone, low random cortisol level, and low TSH, consistent with pituitary insufficiency.

For management, checkpoint inhibitor therapy was held and the patient was treated with prednisone 1mg/kg for 2 weeks, with excellent clinical response, including resolved headaches and improved energy. Follow-up MRI demonstrated resolution of the pituitary enlargement.

Following resolution of initial symptoms, this patient was initially resumed on single agent nivolumab, however due to progression of disease was changed to trametinib (MEK inhibitor antibody) and dabrafenib (BRAF inhibitor antibody) for targeted BRAF mutated melanoma. At the time of this report, the patient has had recurrence hypothyroidism and is undergoing repeat endocrinological evaluation for recurrent hypopituitarism.

Discussion

CTLA-4 and PD1 are immune-checkpoint proteins involved in the regulation of T-cell proliferation. Inhibition of these proteins results in increased T-cell activation, which has shown positive effects on the treatment of melanoma, although the mechanism is not known (4). However, decreased regulation of T-cell activation leads to less specific immune activity, which results in immune-related adverse events (1).

Of these, panhypopituitarism can be one of the most profound. Symptoms of combination immune checkpoint inhibitor therapy induced autoimmune hypophysitis are variable and can include headache, fatigue, hypopituitarism, and/or hyponatremia, as were seen in this patient. Vision changes and other endocrinopathies, such as type 1 diabetes and diabetes insipidus, can also be seen, although was not present in this case (2,5).

While hypophysitis can occur with ipilimumab alone (up to 17% incidence), frequency and severity is greater when combined with nivolumab (5). Treatment consists of discontinuation, corticosteroids, and hormone replacement. Recovery of hormone function, particularly of corticotrophins, is variable (1).

Conclusion

As new cancer therapies emerge, physicians must remain aware of the potential for unique adverse effects – such as those occurring with immune checkpoint inhibitor therapies, including hypophysitis. As the imaging appearance of hypophysitis is not specific, understanding the clinical context in which it occurs can aid radiologists in recognizing it as a possible diagnosis and help guide appropriate clinical management.

References